LENZ (LENZ Therapeutics) Other Gross PPE : $1.44 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Other Gross PPE?

LENZ Therapeutics's Other Gross PPE for the quarter that ended in Dec. 2024 was $1.44 Mil.

LENZ Therapeutics's quarterly Other Gross PPE increased from Jun. 2024 ($1.89 Mil) to Sep. 2024 ($1.91 Mil) but then declined from Sep. 2024 ($1.91 Mil) to Dec. 2024 ($1.44 Mil).

LENZ Therapeutics's annual Other Gross PPE increased from Dec. 2022 ($0.25 Mil) to Dec. 2023 ($0.33 Mil) and increased from Dec. 2023 ($0.33 Mil) to Dec. 2024 ($1.44 Mil).

LENZ Therapeutics Other Gross PPE Historical Data

The historical data trend for LENZ Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Other Gross PPE Chart

LENZ Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Gross PPE

0.01

0.25

0.33

1.44

LENZ Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial						0.33	0.63	1.89	1.91	1.44

LENZ Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

LENZ Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

445 Marine View Avenue, STE No. 320, Del Mar, CA, USA, 92014

Website

https://www.lenz-tx.com

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.